Drugs / BR3409-1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06879158 Comparator | Nov 2024 → Jan 2025 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06879132 Comparator | Nov → Dec 2024 | type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR3409-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879158 ↗ |